Articles by Stephanie Sutton - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

Articles by Stephanie Sutton

AstraZeneca and BMS Extend Diabetes Alliance

Aug 13, 2012

AstraZeneca has paid approximately $3.2 billion to extend its diabetes alliance with Bristol-Myers Squibb (BMS), following BMS’s recently completed acquisition of Amylin Pharmaceuticals.

UK invests in $12.5-million Stem-Cell Institute

Aug 10, 2012

The UK is to invest £8 million ($12.5 million) in a new center that will be dedicated to stem-cell biology and medicine, with the aim of developing new therapeutic approaches to illnesses that currently have no effective treatments.

Novartis in Cancer Collaboration with University

Aug 6, 2012

Novartis has entered into a global collaboration with the University of Pennsylvania in the US to research, develop and commercialise targeted cancer therapies.

EU Issues Top Counterfeit List

Jul 30, 2012

A report from the European Commission shows that fake pharmaceuticals were the top articles detained by European-Union customs in 2011.

UK Consults on Early Medicines Access

Jul 23, 2012

The UK's Medicines and Healthcare products Regulatory Agency has launched a public consultation regarding a scheme that could provide patients with access to unlicensed medicines in Phase II or III clinical trials.

GSK to Acquire Human Genome Sciences for $3.6 Billion

Jul 18, 2012

GlaxoSmithKline has announced that it will acquire Human Genome Sciences (HGS) for $14.25 per share in cash, or approximately $3.6 billion on an equity basis.

EMA Finalizes Pharmacovigilance Guidelines

Jun 28, 2012

The European Medicines Agency has published its first set of finalized guidelines concerning good pharmacovigilance practices.

EMA Investigates Roche for Deficiencies in Safety Reporting

Jun 28, 2012

The European Medicines Agency has launched an investigation into Roche after an inspection found that thousands of potential safety reports, including 15161 deaths, connected to Roche medicines had not been evaluated to determine whether they should be reported to regulators as adverse drug reactions.

Merck Serono Announces Final Restructuring Plan

Jun 21, 2012

Merck Serono has revealed its final “final efficiency program†for operations in Switzerland, which includes confirmation of the closure of sites in Geneva and Coinsins and their associated job cuts.

ADVERTISEMENT

ADVERTISEMENT

Click here